Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

Implantable drug delivery systems (IDDS) are an attractive alternative to conventional drug
administration routes. Oral and injectable drug administration are the most common routes …

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults
across different stages, phases, and symptom domains. Method: Guidelines were developed …

METHODS A group of 8 experts on the management of schizophrenia and LAIs met to
evaluate the evidence and to develop a set of recommendations regarding the clinical use …

The availability of long-acting injectable (LAI) antipsychotics for the treatment of
schizophrenia provides clinicians with options that deliver continuous drug exposure and …

Aims: To examine medication adherence and discontinuation in two separate groups of
patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting …

Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

Objective: This study compared relapse prevention and acceptability of long-acting
injectable (LAI) antipsychotics in the maintenance treatment of adults with nonaffective …

Long-acting injectable (LAI) drug products enable the controlled release of a drug over an
extended duration of time to improve the therapeutic effect, safety profile, or administration of …